Trevena begins heart failure drug study
TRV120027 is a beta-arrestin biased angiotensin II type 1 receptor (AT1R) ligand, the first biased ligand designed to treat patients with AHF. The randomised, placebo-controlled, double-blind, dose-ranging Phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.